iteriontherapeutics.com valuation and analysis

Robots.txt Information
Robot Path Permission
GoogleBot / ✔
BingBot / ✔
BaiduSpider / ✔
YandexBot / ✔ 
User-agent: * Disallow:
Meta Tags
Title Iterion
Description About Us Our Science Our Programs Collaborations News Publications Contact Us Transforming cancer care through TBL1 inhibition Tegavivint: A novel and dif
Keywords N/A
Server Information
WebSite iteriontherapeutics faviconiteriontherapeutics.com
Host IP 107.180.2.151
Location United States
Related Websites
Site Rank
More to Explore
iteriontherapeutics.com Valuation
US$2,057,337
Last updated: 2023-05-02 18:58:43

iteriontherapeutics.com has Semrush global rank of 5,144,664. iteriontherapeutics.com has an estimated worth of US$ 2,057,337, based on its estimated Ads revenue. iteriontherapeutics.com receives approximately 237,385 unique visitors each day. Its web server is located in United States, with IP address 107.180.2.151. According to SiteAdvisor, iteriontherapeutics.com is safe to visit.

Traffic & Worth Estimates
Purchase/Sale Value US$2,057,337
Daily Ads Revenue US$1,900
Monthly Ads Revenue US$56,973
Yearly Ads Revenue US$683,669
Daily Unique Visitors 15,826
Note: All traffic and earnings values are estimates.
DNS Records
Host Type TTL Data
iteriontherapeutics.com. 10800 A iteriontherapeutics.com. 10800 IP: 107.180.2.151
iteriontherapeutics.com. 3600 NS iteriontherapeutics.com. 3600 NS Record: ns45.domaincontrol.com.
iteriontherapeutics.com. 3600 NS iteriontherapeutics.com. 3600 NS Record: ns46.domaincontrol.com.
HtmlToTextCheckTime:2023-05-02 18:58:43
About Us Our Science Our Programs Collaborations News Publications Contact Us Transforming cancer care through TBL1 inhibition Tegavivint: A novel and differentiated mechanism to modulate the Wnt/beta-catenin pathway and treat cancer Iterion Therapeutics : The TBL1 Inhibitor Company Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company’s lead product, tegavivint , is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1) , a novel downstream target of the canonical Wnt/beta-catenin signaling pathway. Iterion is advancing clinical programs of tegavivint in tumor types with a high prevalence of Wnt/beta-catenin activating mutations, such as hepatocellular carcinoma . In parallel, the company has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials in acute myeloid leukemia, non small cell
HTTP Headers
HTTP/1.1 301 Moved Permanently
Date: Mon, 25 Oct 2021 04:15:00 GMT
Server: Apache
Location: https://iteriontherapeutics.com/
Content-Type: text/html; charset=iso-8859-1

HTTP/2 200 
x-powered-by: PHP/7.2.34
link: ; rel="https://api.w.org/", ; rel=shortlink
content-type: text/html; charset=UTF-8
date: Mon, 25 Oct 2021 04:15:01 GMT
server: Apache
iteriontherapeutics.com Whois Information
Domain Name: ITERIONTHERAPEUTICS.COM
Registry Domain ID: 2322571494_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2020-10-23T13:35:51Z
Creation Date: 2018-10-17T18:25:53Z
Registry Expiry Date: 2022-10-17T18:25:53Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: abuse@godaddy.com
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS45.DOMAINCONTROL.COM
Name Server: NS46.DOMAINCONTROL.COM
DNSSEC: unsigned
>>> Last update of whois database: 2021-09-13T08:55:41Z <<<

Copyright © 2022 WebZZ.US 0.0239